ATMF report tackles global access to antibiotics

After introducing readers to the threat that antimicrobial resistance (AMR) poses to global health, the article highlights one of the report’s key insights, which is the lack of sufficient access and stewardship planning by pharma companies in LMICs, where AMR is highest. 

The article also notes a more positive observation from the report: a trend among pharma companies in scope seeking clinical testing of AMR products for paediatric use. This is encouraging, as children under 5 years of age are disproportionately affected by AMR and market approval for paediatric drug use typically takes up to ten years longer than adult use.